Mild cognitive impairment (MCI) may represent an early, and potentially treatable, phase of dementing disorders. Its correct clinical identification is therefore of paramount importance. Here, Dr Larner analyses data from a selection of short cognitive screening instruments (CSIs) employed in a secondary care setting to measure various parameters for diagnosis of MCI and to establish whether any of the instruments have superior diagnostic utility.
Introduction
Early diagnosis of cognitive disorders would seem to offer the best chance for their effective treatment, as in other neurological disorders and, indeed, in other spheres of medicine. To this end, the definition of disease biomarkers, which reflect the clinicobiological features of dementing diseases, and their incorporation in diagnostic criteria, 1 offers perhaps the best possibility of early diagnosis, possibly even in the presymptomatic stages of disease. For Alzheimer's disease (AD), this presymptomatic phase may last for decades. 2, 3 Likewise, the early symptomatic phases of dementing disorders might also represent a significant opportunity for treatment, particularly if disease-modifying therapies can be discovered and brought to the clinical arena. Some consensus has grown up around the concept of mild cognitive impairment (MCI), not only as a prodromal phase of AD, but also of the cognitive impairment associated with other brain disorders, which can progress to dementia, including Parkinson's disease 4 and cerebrovascular disease (vascular cognitive impairment), 5 and possibly also frontotemporal dementia. 6 The category of 'MCI' thus has the advantage of flexibility, accepting that it encompasses significant heterogeneity both with respect to aetiology and prognosis (conversion rate to dementia). 7 Other terminology may also sometimes be used to denote such patients, such as 'mild cognitive disorder' (as in ICD10), 'cognitive impairment no dementia', 8 and 'mild cognitive dysfunction'. 9 Although some criteria have sought to eschew MCI as a category relevant to AD, in favour of a more definitive diagnosis of 'early AD', other criteria persist with MCI. 10 The most recent AD diagnostic criteria are partly based around sophisticated neuroimaging and cerebrospinal neurochemistry biomarkers, tapping into the clinicobiological aspects of disease. 1 However, such investigations may not be readily available outside of specialist centres, and hence the simpler cognitive screening instruments (CSIs), which may be used to supplement clinical history taking, may still be the initial investigation in patients suspected of dementia or MCI or in patients with memory complaints. Hence it is pertinent to examine the screening utility of these CSIs for the early stages of disease when disease-modifying therapy might have the best chance of efficacy. Although, as their nomenclature indicates, these are screening and not diagnostic tests, nevertheless they are often subjected to test accuracy studies using essentially the same methodology as for diagnostic tests. 11 As proof-of-concept, a meta-analysis of studies of the Mini-Mental State Examination, perhaps the most commonly used CSI and a benchmark for other such instruments, has shown its diagnostic validity in MCI. 12 The aim of the study presented here was to collate information from several pragmatic studies of short CSIs (ie those taking approximately 5-10 minutes to administer), undertaken in a secondary care setting (a dedicated cognitive disorders clinic based in a regional neuroscience centre), to examine their screening utility for the diagnosis of MCI, versus either dement i a o r s u b j e c t i v e m e m o r y complaint. Because of the time of administration criterion, certain iterations of the Addenbrooke's Cognitive Examination (ACE, ACE-R, ACE-III) which usually take around 15-20 minutes to administer were not included, but the mini-Addenbrooke's Cognitive Examination was.
Materials and methods
The datasets from several pragmatic prospective diagnostic test accuracy studies undertaken in the author's clinic were used, [13] [14] [15] [16] [17] [18] which examined the following short performance- 23 and the Six-item Cognitive Impairment Test (6CIT). 24 Where appropriate, data from pragmatic studies of informant-based screeni n g i n s t r u m e n t s w e r e a l s o included, 25, 26 specifically AD8, 27 and the short and screening versions of the Zarit Burden Interview (ZBI), 28, 29 which has been examined as a possible informant-based CSI. 26 Study details (setting, sample size, prevalence of dementia and MCI in the case mix, sex ratio, age range) are shown in Table 1 .
For most of these instruments, lower scores indicate worse cognitive function (MMSE, MMP, MoCA, TYM, M-ACE), but others are negatively scored such that lower values are better and higher are worse (6CIT, AD8, ZBI).
These studies followed a standardised format used in this clinic, 30 The following three forms of data analysis were performed, some based on previously published results, 11, 30 others requiring re-analysis of individual study data.
Firstly, significance testing based on the null hypothesis was undertaken comparing mean test scores for patients with dementia versus MCI, and for patients with MCI versus no cognitive impairment. Since all cases referred to the outpatient clinics in which these pragmatic studies were undertaken have at minimum subjective memory complaint (SMC), there was no 'normal' control group, as befits pragmatic (or 'phase III') diagnostic test accuracy studies. 11 A value of p<0.05 was taken as significant.
Significance tests are, of course, post hoc, based on aggregate data once diagnoses have been made, and hence are of limited use in clinical practice where diagnosis is not known beforehand, and parameters such as sensitivity, specificity, predictive values and likelihood ratios are more typically used. 11, 30 Hence the second analysis was to calculate these measures of discrimination for MCI diagnosis versus SMC, since this would most likely correspond to treatment threshold if any disease-modifying therapy were available. All these descriptors of outcome are dependent on the cut-off, cut point, threshold or dichotomisation point of the test scores selected by the investigator(s), which choice may have a major impact on these values. 18, 31, 32 Previously published cut-off scores for each CSI were used, where available, to minimise the risk of bias from defining optimal cut-off post hoc based on study data. 33 (NB two different cut-offs are cited for M-ACE. 23 )
Single, global or unitary, indicators of test diagnostic performance have also been described, one of which is effect size, most frequently expressed as Cohen's d (the difference of the means of two groups divided by the weighted pooled standard deviations of the groups). This measure is independent of test cut-off chosen, and may be qualified (effect sizes of 0.2 to 0.3 are small, 0.5 medium, and ≥0.8 large). 34 Hence the third analysis was calculation of effect size (Cohen's d) for the diagnosis of MCI versus SMC, some results from which have been previously reported. 35 This approach to test comparison was deemed preferable to weighted comparisons, 17 latter are highly dependent on differences in test sensitivity which in turn are highly dependent on the test cut-off chosen. 11 
Results
As regards significance testing (see Table 2 ), for all the short performance-based CSIs examined (MMSE, MMP, MoCA, TYM, M-ACE, 6CIT) the null hypotheses that scores did not differ significantly between patients with dementia and patients with MCI was rejected (Table 2a ). This was also true for AD8, an informant-based CSI (Table 2b ), but not on either version of the ZBI, scores on which are recognised not to correlate with performance-based CSIs. 26 Likewise, examining the null hypotheses that scores did not differ significantly between patients with MCI and patients with SMC (see Table 3 ) was rejected for all the short performance-based CSIs examined (MMSE, MMP, MoCA, TYM, M-ACE, 6CIT; Table 3a) ; only a trend was evident for AD8 for this differential diagnosis (Table 3b) .
Measures of discrimination were calculated for diagnosis of MCI versus SMC using specified test cut-offs for those short CSIs reaching or tending to statistical significance on null hypothesis testing (see Table 4 ). Evidently, of the performance-based CSIs examined, MMSE, MMP, MoCA, and M-ACE ≤25/30 were highly sensitive for MCI diagnosis (Table 4a) , as was the informant-based AD8 (Table 4b) , with the risk of false positives; whereas M-ACE ≤21/30 and 6CIT were more specific, with risk of false negatives.
Cohen's d effect sizes for MCI diagnosis for short performancebased CSIs are shown in Table 5 . Of note, the effect size was particularly impressive for two tests, MoCA and M-ACE.
Discussion
The data reported here suggest that several short performance-based CSIs may be used to identify MCI cases with confidence, based on the findings of pragmatic diagnostic (or technically 'screening') test accuracy studies. 11 Such studies should have high external validity, and the results may be transferable to other similar clinics, informing day-to-day clinical practice.
Of course, this approach is not without its shortcomings. Pragmatic studies, broadly inclusive with respect to patient age and comorbidity, lack the power of proof-of-concept studies with patient groups pre-selected by diagnosis, although the latter approach is of course alien to day-to-day clinical practice. Moreover, these pragmatic studies were cross-sectional, again the idiom of clinical practice, rather than longitudinal, with consequent risk of inaccurate criterion diagnosis, particularly when attempting to separate MCI and SMC. Furthermore, the use of purely quantitative aggregate measures may not necessarily be helpful clinically (see the Materials and methods section above): since MCI patients may be anticipated to do well on certain aspects of CSIs and poorly on others (eg memory recall in amnestic MCI), so the qualitative pattern of impairment on these tests may also be useful clinically, rather than simply using the overall test scores. Nevertheless, pragmatic studies, as analysed in this report, may give indications of potential test utility as a support for MCI diagnosis, or the requirement for further patient investigation or longitudinal assessment. It was not the purpose of this analysis directly to compare the different CSIs, since the different studies from which the data were taken were not (and never could be) exactly comparable. Nevertheless, the studies being examined shared a similar setting, methodology (eg application of reference standard for diagnosis) and analysis, thereby minimising variability, although this could not be entirely excluded (eg dementia prevalence, based on the case mix seen in series of unselected consecutive patients). Nevertheless, the suggestion that emerges is that MMSE, MMP, MoCA, and M-ACE (cut off ≤25/30) may be acceptable as screeners for MCI in this clinical setting if high sensitivity is desired, as is often the case for clinical practice. However, the high false positive rate associated with high sensitivity would argue against the use of these instruments for use in clinical trials where high specificity and low false positive rate is more desirable. 1 With, in addition, their large effect size (Cohen's d), MoCA and M-ACE may be of particular value for MCI diagnosis. Since MoCA was designed specifically to identify MCI cases, 21 this finding is perhaps not unexpected.
There are, of course, other CSIs that might be used for MCI diagnosis, which were not encompassed in this study, such as the Quick mild cognitive impairment (Qmci) screen, 38 DemTect, 39, 40 MCI Screen, 41 ABCS 135, 42 and even the Clock Drawing Test. 43 An important issue for all these possible screening instruments for MCI will be to examine how well they correlate with biomarkers of dementia disorders, such as AD. 44 Another avenue for future study would be combining performancebased and informant-based CSIs. This has been attempted for diagnosis of dementia (MMSE and AD8; 6CIT and AD8), 25 with improved sensitivity for MMSE and AD8 in the parallel ('Or' rule) paradigm.
In conclusion, a number of short performance-based CSIs may be helpful in clinical practice as a first step to screen for the diagnosis of MCI. Dependent upon their Table 4 . Measures of discrimination (with 95% confidence intervals) for diagnosis of MCI versus SMC at specified cut-offs using those short cognitive screening instruments reaching or tending to statistical significance on null hypothesis testing (see Table 3 ) in pragmatic studies results, more detailed assessment including sophisticated biomarker studies and formal cognitive assessment may be indicated to establish or refute the diagnosis of MCI. 
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